Medicines acting on RARB
Retinoic acid receptor beta. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
Medicines acting on RARB
most-trialled first| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Isotretinoin CHEMBL547 |
Retinoic acid receptor agonist Agonist Small molecule |
ChEMBL only | 10 |
| Tretinoin CHEMBL38 |
Retinoic acid receptor agonist Agonist Small molecule |
✓ Both | 7 |
| Acitretin CHEMBL1131 |
Retinoid receptor agonist Agonist Small molecule |
ChEMBL only | 3 |
| Adapalene CHEMBL1265 |
Retinoic acid receptor agonist Agonist Small molecule |
ChEMBL only | 2 |
| Tamibarotene CHEMBL25202 |
Retinoic acid receptor beta agonist Agonist Small molecule |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
Diseases these medicines are tested for
by number of RARB medicines| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Myelodysplastic syndrome | 3 | Phase 3 |
| COVID-19 | 2 | Phase 3 |
| Acute myeloid leukemia | 2 | Phase 3 |
| Non-small cell lung carcinoma | 2 | Phase 3 |
| Rosacea | 2 | Phase 3 |
| Alzheimer disease | 2 | Phase 2/3 |
| Acanthosis nigricans | 1 | Phase 3 |
| Autoimmune thrombocytopenic purpura | 1 | Phase 3 |
| Autosomal recessive congenital ichthyosis | 1 | Phase 3 |
| Breast cancer | 1 | Phase 3 |
| Ganglioneuroblastoma | 1 | Phase 3 |
| Glioma | 1 | Phase 3 |
| Hypopharynx squamous cell carcinoma | 1 | Phase 3 |
| Laryngeal squamous cell carcinoma | 1 | Phase 3 |
| Malignant glioma | 1 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
How this page is built
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
- Open Targets Platform, target ENSG00000077092 ↗ target record, CC0 1.0
- ChEMBL mechanism of action and drug indication data ↗ curated by EMBL-EBI, CC BY-SA 3.0
- IUPHAR/BPS Guide to PHARMACOLOGY 2026.3 ↗ expert-curated ligand-target interactions; database ODbL, contents CC BY-SA 4.0
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 31 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.